Causally-inspired meta-representation learning framework for predicting patient-specific clinical responses to drug combinations
TL;DR
CaMeRe, a Causally-inspired Meta-representation learning framework designed to predict patient-specific clinical Response to drug combinations, exhibited robust multi-domain generalization performance across multiple clinical drug combination response datasets and PDXs drug combination response datasets and generalization scenarios, but also had better interpretability.
Abstract
Large-scale prediction and assessment of clinical patient responses (i.e., RECIST class) to drug combinations remains challenging due to scarce patient-derived data. The existing prediction methods mainly rely on cancer cell line models. However, substantial biological heterogeneity between cancer cell lines and cancer patients within same tissues, as well as the heterogeneity between one tissue and another, often limit the generalizability of these methods in clinical patients. To overcome these limitations, here we present CaMeRe, a Causally-inspired Meta-representation learning framework designed to predict patient-specific clinical Response to drug combinations. In situations where stable causal factors and domain-specific response-modulating factors are unobservable, explicit discrete domain labels are unavailable, and data is scarce, CaMeRe designed a domain-invariant causal representation learning (DICRL) model guided by the invariant information bottleneck theory and causal intervention invariance principle, and also built a meta-learning framework with bi-level domain generalization to optimize DICRL model for achieving multi-domain generalization within and across tissues. By integrating the causal representation learning and meta learning framework, CaMeRe not only exhibited robust multi-domain generalization performance across multiple clinical drug combination response datasets and PDXs drug combination response datasets and generalization scenarios, but also had better interpretability. We applied CaMeRe to predict drug-combination response scores for 3,423 patients across 542,080 drug combinations. The predicted scores were significantly associated with biomarkers of known drug combinations and enabled the prioritization of candidate drug combinations across 11 cancer types, with stronger support from literature and clinical trial evidences than random baselines. We believe that CaMeRe can be a useful tool for predicting large-scale clinical individual drug combination responses and it has broad clinical applications.